Back to Results

Swedish Orphan Biovitrum AB ADR (BIOV.F)

Swedish Orphan Biovitrum AB ADR is a depositary receipt representing the shares of Swedish Orphan Biovitrum AB (publ), a Stockholm-based biopharma company founded in 1939. The business focuses on medicines for haematology, immunology, and specialty care, with operations across Europe, North America, the Middle East, Asia, and Australia. Its portfolio includes treatments such as Alprolix, ALTUVOCT, Aspaveli/Empaveli, Doptelet, Elocta/Eloctate, Gamifant, Kineret, Orfadin, Synagis, VONJO, and Zynlonta, alongside other medicines including Akynzeo, Jyseleca, Tegsedi, and Waylivra. Swedish Orphan Biovitrum also develops drug substances for ReFacto AF/Xyntha for Pfizer and maintains collaboration agreements with Sanofi, Apellis Pharmaceuticals, ADC Therapeutics, and Cartesian Therapeutics.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BIOV.F
$46.70
-4.7% Downside
Fair
—
—
—
Great
—
—
—
0.0%
October 27, 2026
173.1x
3.9x
5.5x
16.554 B
18.753 B
10.6%
64.1%
9.1
—
566.9%
Send a message
Valuation • Fair Value

Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) Fair Value by Valuation Model

Compare the primary fair value estimate for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$46.70

Estimated downside of 4.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$55.93

Discounted cash flow valuation reference.

Ben Graham Formula Value

$3.05

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$29.26

Earnings power value estimate.

Comps Fair Value

$40.38

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

3.058 B

Current operating scale indicator.

Revenue Forecast

3.395 B

Forward revenue estimate.

EBITDA

1.232 B

Current operating profitability reference.

EBITDA Forecast

1.345 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.69

No elevated caution signal from this screen.

Altman Z-Score

9.1

Relatively strong balance-sheet zone.

FCF / Net Income

566.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 27, 2026

Days to Earnings

98

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) Stock Forecast & Technical Outlook

Review Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) Stock FAQ

Quick answers about Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$46.70
Estimated downside 4.7%
Valuation Rating
Overvalued
Estimated downside of 4.7%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is $46.70. This implies an estimated downside of 4.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 4.7% versus the current market price.

An analyst price target for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is not currently available in the latest data file.

The current financial health read for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is October 27, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is 173.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Swedish Orphan Biovitrum AB ADR is 16.554 B.

The current enterprise value listed for Swedish Orphan Biovitrum AB ADR is 18.753 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Swedish Orphan Biovitrum AB ADR is OTC-BIOV.F, and the stock is listed on OTC Markets.

Swedish Orphan Biovitrum AB ADR (OTC-BIOV.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Swedish Orphan Biovitrum AB ADR is 10.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Swedish Orphan Biovitrum AB ADR is 64.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)
Medicenna Therapeutics Corp (MDNAF) Medicenna Therapeutics Corp (MDNAF)